Everolimus-eluting stents in interventional cardiology

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 393-405

  Townsend, Jacob C ^a   Rideout, Phillip ^a   Steinberg, Daniel H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Efficacy; Everolimus eluting stents; Safety

Indexed keywords

EVEROLIMUS; PACLITAXEL; POLYMER; RAPAMYCIN; ZOTAROLIMUS; CARDIOVASCULAR AGENT; DRUG DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BARE METAL STENT; BIOCOMPATIBILITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEVICE SAFETY; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG RELEASE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVASCULARIZATION; REVIEW; STENT THROMBOSIS; CORONARY ARTERY DISEASE; INSTRUMENTATION; PATIENT SELECTION; PROSTHESIS; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PATIENT SELECTION; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84871907598     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S23388     Document Type: Review

References (81)

1. Coronary angioplasty versus medical therapy for angina: The second randomised intervention treatment of angina (RITA-2) trial. Rita-2 trial participants. Lancet. 1997;350:461-468.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med. 1994;331: 489-495.
3. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
4. Leon MB, Nikolsky E, Cutlip DE, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. JACC Cardiovasc Interv. 2010;3:1043-1050.
5. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) iii trial. Circulation. 2009;119: 680-686.
6. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356: 1503-1516.
7. Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J. 2005;26:881-889.
8. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
9. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: The Total Occlusion Study of Canada (TOSCA). Circulation. 1999;100:236-242.
10. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-2089.
11. Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. 2006;70:1026-1029.
12. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
13. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
14. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350: 221-231.
15. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28:721-726.
16. Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial. Am J Transplant. 2012;12:694-705.
17. Chan S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer. 2004;91:1420-1424.
18. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164-2170.
19. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104: 2007-2011.
20. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: Focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag. 2008;4:31-38.
21. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: Five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299-1304.
22. Weisz G, Leon MB, Holmes DR Jr, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (sirolimus-eluting stent in de-novo native coronary lesions) trial. J Am Coll Cardiol. 2009;53:1488-1497.
23. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-195.
24. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093-1104.
25. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645.
26. Grube E, Silber S, Hauptmann KE, et al. Taxus I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
27. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
28. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-1959.
29. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA. 2006;295:895-904.
30. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662.
31. Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: Results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization late trial. Circulation. 2011;123:2819-2828.
32. Galloe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: The SORT OUT II randomized trial. JAMA. 2008;299:409-416.
33. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DESCOVER Registry. Circulation. 2006;114:2154-2162.
34. Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: Results from a large prospective multicenter registry - STENT group. J Am Coll Cardiol. 2007;50:1214-1222.
35. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45:1135-1141.
36. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet. 2007;369:667-678.
37. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (last) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
38. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591.
39. Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv. 2012;5:12-20.
40. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
41. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation. 2004;109:701-705.
42. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342.
43. Hansi C, Arab A, Rzany A, Ahrens I, Bode C, Hehrlein C. Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. Catheter Cardiovasc Interv. 2009;73:488-496.
44. Chitkara K, Pujara K. Drug-eluting stents in acute coronary syndrome: is there a risk of stent thrombosis with second-generation stents? Eur J Cardiovasc Med. 2010;1:20-24.
45. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, 1lind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
46. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the endeavor zotarolimus-eluting stent versus the taxus paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55:543-554.
47. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48:2440-2447.
48. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): A randomised controlled superiority trial. Lancet. 2010;375:1090-1099.
49. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: The ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol. 2010;56:1187-1195.
50. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109:2168-2171.
51. Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT FIRST trial. EuroIntervention. 2005;1:58-65.
52. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Euro Intervention. 2006;2:286-294.
53. Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the Xience V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv. 2009;2:339-347.
54. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913.
55. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674.
56. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (clinical evaluation of the Xience V everolimus eluting coronary stent system) IV trial. J Am Coll Cardiol. 2011;58:19-25.
57. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet. 2010;375:201-209.
58. Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison Of The Everolimus Eluting Xience-V Stent With The Paclitaxel Eluting Taxus Liberte stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58:11-18.
59. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V stent evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol. 2009;54:269-276.
60. Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: The EXCELLENT (Efficacy of Xience/Promus versus Cypher to reduce late loss after stenting) randomized trial. J Am Coll Cardiol. 2011;58:1844-1854.
61. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
62. Kastrati A, Massberg S, Ndrepepa G. Is diabetes the Achilles' heel of limus-eluting stents? Circulation. 2011;124:869-872.
63. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: Collaborative Network meta-analysis. BMJ. 2008;337:a1331.
64. Kim WJ, Lee SW, Park SW, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES trial. Circulation. 2011;124:886-892.
65. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124:893-900.
66. Valenti R, Migliorini A, Signorini U, et al. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur Heart J. 2008;29:2336-2342.
67. Valenti R, Vergara R, Migliorini A, et al. Comparison of everolimus-eluting stent with paclitaxel-eluting stent in long chronic total occlusions. Am J Cardiol. 2011;107:1768-1771.
68. Tamura T, Kimura T, Morimoto T, et al. Three-year outcome of sirolimus-eluting stent implantation in coronary bifurcation lesions: The provisional side branch stenting approach versus the elective two-stent approach. Euro Intervention. 2011;7:588-596.
69. Lansky AJ, Yaqub M, Hermiller JB, et al. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: Three-year results from the SPIRIT III randomised trial. Euro Intervention. 2010;6 Suppl J:J44-J52.
70. Burzotta F, Trani C, Todaro D, et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv. 2011;4:327-335.
71. Herrador JA, Fernandez JC, Guzman M, Aragon V. Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions. Catheter Cardiovasc Interv. 2011;78:1086-1092.
72. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA. 2006;295:1253-1263.
73. Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial. JAMA. 2006;295:1264-1273.
74. Almalla M, Schroder JW, Pross V, Stegemann E, Marx N, Hoffmann R. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. Am J Cardiol. 2011;108:518-522.
75. Cannon LA, Simon DI, Kereiakes D, et al. The Xience nano™ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. Catheter Cardiovasc Interv. November 25, 2011.
76. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [Promus Element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57:1700-1708.
77. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578-1588.
78. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: Results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48:253-261.
79. Schafer PE, Sacrinty MT, Cohen DJ, et al. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes. 2011;4:408-415.
80. Eisenstein EL, Leon MB, Kandzari DE, et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the Cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv. 2009;2:1199-1207.
81. Leon MB, Kandzari DE, Eisenstein EL, et al. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (randomized, controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Taxus paclitaxel-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv. 2009;2:1208-1218.